resmetirom Rezdiffra NASH MASH
Selected indexed studies
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (J Hepatol, 2024) [PMID:38851997]
- Epidemiology of metabolic dysfunction-associated steatotic liver disease. (Clin Mol Hepatol, 2025) [PMID:39159948]
- Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. (Clin Gastroenterol Hepatol, 2024) [PMID:39038768]
_Worker-drafted node — pending editorial review._
Connections
resmetirom Rezdiffra NASH MASH is a side effect of
Sources
- Resmetirom: First Approval. (2024) pubmed
- Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. (2024) pubmed
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) pubmed
- Epidemiology of metabolic dysfunction-associated steatotic liver disease. (2025) pubmed
- Metabolic reprogramming in liver fibrosis. (2024) pubmed
- Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). (2025) pubmed
- Resmetirom: The First Disease-Specific Treatment for MASH. (2025) pubmed
- Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. (2025) pubmed
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. (2024) pubmed
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). (2024) pubmed